How can I distinguish active from non‑active secondary progressive multiple sclerosis for coding in a patient on disease‑modifying therapy, given that the therapy may suppress new or worsening brain activity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Distinguishing Active from Non-Active Secondary Progressive MS in Patients on DMT

In patients on disease-modifying therapy, classify secondary progressive MS as "active" if there is evidence of relapses OR new/enlarging T2 lesions OR gadolinium-enhancing lesions on MRI within the past 12 months, regardless of whether the DMT is suppressing some activity—the presence of any breakthrough inflammatory activity defines active disease. 1

Key Diagnostic Framework

Definition of Active SPMS

Active SPMS requires either clinical OR radiological evidence of ongoing inflammatory activity:

  • Clinical activity: ≥1 relapse in the past 12 months 1
  • Radiological activity:
    • ≥1 gadolinium-enhancing lesion on current MRI, OR
    • ≥1 new or enlarging T2 lesion compared to reference scan 1

Definition of Non-Active SPMS

Non-active SPMS is characterized by:

  • No relapses in the past 12 months (or 2 years in some definitions) 2
  • No gadolinium-enhancing lesions on current MRI
  • No new or enlarging T2 lesions compared to reference scan 2

Critical Considerations When DMT is Suppressing Activity

The DMT Paradox

The fact that a patient is on DMT does not change the classification criteria—you assess activity based on what breakthrough inflammatory events occur despite treatment. 1

  • DMTs can significantly reduce gadolinium-enhancing lesions and suppress active inflammation 1
  • However, subclinical disease activity occurs much more frequently than clinically apparent relapses 1
  • Even patients classified as "non-active" at baseline can show disease activity during follow-up: in the EXPAND trial, 53% of non-active SPMS patients demonstrated disease activity on study 2

MRI is Superior to Relapse Monitoring

MRI detects the majority of disease activity in SPMS patients on DMT:

  • In real-world data, 59.1% of active SPMS cases were identified by MRI alone, versus only 12.7% by relapse alone 2
  • In the EXPAND trial, 74.1% of disease activity in initially "non-active" patients was detected by MRI, versus only 8.4% by relapse 2
  • This means relying on clinical relapses alone will miss most active disease 2

Practical Imaging Protocol for Classification

Required MRI Approach

Brain MRI with and without gadolinium contrast is essential for accurate classification: 1

  1. Baseline/Reference Scan: Establish before starting or switching DMT, then obtain new baseline at 3-6 months after treatment initiation 1

  2. Follow-up Imaging:

    • Yearly brain MRI while on DMT for routine monitoring 1
    • MRI with gadolinium when detecting or confirming disease activity is required 1
    • Earlier imaging (within 6 months) if unexpected clinical worsening occurs 1
  3. Gadolinium Use: Contrast is specifically recommended when:

    • Showing disease activity is required to initiate or change DMT 1
    • Patient has diffuse/confluent chronic lesions where new T2 activity is difficult to detect 1
    • No recent reference MRI (done <3-6 months ago) is available 1

Spinal Cord Imaging

Add cervical/thoracic spine MRI with contrast when: 1

  • Symptoms suggest spinal cord involvement
  • Worsening disability cannot be explained by brain MRI
  • Patient has spinal cord phenotype (few brain lesions)

Common Pitfalls to Avoid

1. Under-Monitoring Non-Active Patients

Critical error: In real-world practice, only 58.7% of non-active SPMS patients received MRI in the past year, compared to 87.7% of active patients 2. This is problematic because:

  • Most disease activity is detected by MRI, not clinical relapse 2
  • Non-active patients can develop breakthrough activity (53% did in EXPAND) 2

2. Timing of MRI Relative to Steroids

  • Obtain MRI before steroid treatment when possible 1
  • Steroids shorten the duration of gadolinium enhancement 1

3. Misinterpreting Early Post-Treatment Changes

  • New lesions appearing within 3-6 months of DMT initiation may represent pre-treatment disease 1
  • Always establish a new baseline 3-6 months after treatment start 1

4. Confusing Progression with Activity

These are separate concepts:

  • Activity = inflammatory events (relapses, new lesions, gadolinium enhancement)
  • Progression = gradual worsening independent of relapses
  • A patient can have progression without activity (non-active SPMS) or progression with activity (active SPMS) 3, 4

Coding Algorithm

Step 1: Review past 12 months for relapses
├─ YES → Code as Active SPMS
└─ NO → Proceed to Step 2

Step 2: Compare current MRI to reference scan (ideally <6 months old)
├─ Gadolinium-enhancing lesions present? → YES → Code as Active SPMS
├─ New T2 lesions present? → YES → Code as Active SPMS
├─ Enlarging T2 lesions present? → YES → Code as Active SPMS
└─ None of above → Code as Non-Active SPMS

Step 3: Document DMT status separately
└─ Note: DMT use does not change activity classification

Special Consideration: The "Suppressed but Active" Patient

A patient may have minimal breakthrough activity on effective DMT but still qualify as "active"—even a single new T2 lesion can prompt therapy changes in clinical practice 1. The classification reflects the presence of any inflammatory activity, not the degree of suppression achieved. This is clinically relevant because:

  • Younger patients with active SPMS show higher efficacy from DMTs like siponimod 5
  • The therapeutic window is enhanced in those with shorter disease duration 3
  • Early identification of active progressive MS maximizes treatment benefit 3, 6

The key principle: classify based on what inflammatory activity breaks through despite DMT, not on what the DMT might be preventing.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.